Indaptus Therapeutics Inc (INDP): Broker Consensus Forecast
The price history on the Indaptus Therapeutics (INDP) chart demonstrates the dynamics of an asset whose operating model relies on external contractors for drug synthesis and testing, which fixes the 9.96 indicator. The human capital is based on a stable staff of biochemists with the involvement of specialized lawyers. Business prospects are determined by the implementation of a platform based on inactivated bacteria to combat oncology by stimulating the body's defensive forces.
Analytical breakdowns for Indaptus (INDP)
- price and consensus price forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Indaptus Therapeutics|INDP - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Indaptus Corp|INDP - Company Aggregate Debts|Debts to Book Capitalization Indaptus|INDP - Company Long-Term Debt|Company Short-Term Loans and Borrowings Indaptus Therapeutics|Quick Liquidity Indicator indaptusrx.com
- net income and valuation multiples indicators:
INDP - Net Profit|Projected Future Earnings Indaptus Therapeutics|INDP - Price to Earnings Ratio|Future Price to Earnings Multiple Indaptus Therapeutics Inc|INDP - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Indaptus|INDP - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Indaptus Therapeutics|INDP - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months indaptusrx.com|INDP - Net earnings per share growth this year|Earnings growth forecast for next year Indaptus Therapeutics
General company analysis:INDP indaptusrx.com
Indaptus Therapeutics (INDP) operates under conditions of high regulatory risk and zero revenue while awaiting validation of its immune platform. The current value of 9.96 reflects the weighted average fair value of the asset, where the dynamics of the market target consensus serve as a tool for capital control and trend verification, allowing the investor to assess the reliability of the price movement vector without confirmation from trading volumes.
Competitors of Indaptus Therapeutics
Analyst Median Target argenx.com|Price Target Chart BioNTech BNTX|ABVX: Broker Consensus Forecast|ADMA Bio - Analyst Consensus Forecast|PTGX (Protagonist Corp) - Broker Consensus Forecast|Immunovant, Inc. (IMVT) - Price Target Chart|Forecast Levels Chart KNSA (kiniksa.com)|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Analyst Median Target Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price Target Chart|Broker Consensus Forecast TLSA|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Broker Consensus Forecast VTYX (Ventyx Biosciences Inc.)|Analyst Consensus Forecast THTX|Analyst Consensus Forecast Avalo Therapeutics Inc (AVTX)|Price Target Chart Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Forecast Levels Chart|CLYM: Consensus Target|zurabio.com - Analyst Forecast Prices|ATYR (aTyr) - Consensus Target|Adagene Inc. (ADAG) - Analyst Consensus Forecast|Price Target Chart ImageneBio|Shattuck Therapeutics (STTK) - Analyst Median Target|Consensus Target EQ (Equillium, Inc.)|CNTB (connectbiopharm.com) - Fair Value Consensus|Immunic - Consensus Target|Analyst Forecast Prices ATRA (Atara Biotherapeutics, Inc.)|InflaRx GmbH - Analyst Consensus Forecast|Fair Value Consensus XFOR (x4pharma.com)|ACET: Analyst Consensus Forecast|Average Forecast Price Celularity (CELU)|Price Target Chart INmune Bio Corp|BRNS: Fair Value Consensus|Analyst Consensus Forecast KZR|Analyst Consensus Forecast sabbiotherapeutics.com (SABS)|Price Target Chart Akari Therapeutics Plc AKTX|ENLV (Enlivex Therapeutics Ltd) - Forecast Levels Chart|Q32 Bio Corp - Analyst Consensus Forecast|Average Forecast Price GeoVax Corp|EDSA (Edesa Biotech, Inc.) - Consensus Target|ibioinc.com (IBIO) - Analyst Consensus Forecast|Consensus Target CARM|XTLB (XTL Biopharmaceuticals Ltd) - Analyst Forecast Prices|Analyst Consensus Forecast BOLT|Analyst Median Target hcwbiologics.com|Analyst Consensus Forecast APVO (Aptevo Therapeutics Inc.)|AIM - Consensus Target|ADTX - Price Target Chart|Analyst Median Target GRI Bio Inc GRI|XRTX: Analyst Consensus Forecast|HIND - Analyst Median Target|Price Target Chart Revelation Biosciences|Broker Consensus Forecast SCNI (scinai.com)|Analyst Consensus Forecast CALI|affimed.com - Broker Consensus Forecast|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGMS - Price Target Chart|Forecast Levels Chart ITOS|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc - Fair Value Consensus|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
